Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Autologous Transplantation Using Rituxanbeam

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT00329030Phase 3Completed

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)

Showing all 1 trials

Research Network

Common Treatments

  • Autologous Transplantation Using Rituxanbeam1
  • Autologous Transplantation Using Bexxarbeam1

Active Sponsors

  • Blood and Marrow Transplant Clinical Trials Network1
  • National Cancer Institute (NCI)1
  • National Heart, Lung, and Blood Institute (NHLBI)1

Top Investigators

Related Conditions

  • Lymphoma Bcell1
  • Lymphoma Nonhodgkin1

Activity Timeline